Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.
Identifieur interne : 000567 ( PubMed/Checkpoint ); précédent : 000566; suivant : 000568Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.
Auteurs : H. Verdoux [France] ; E. PambrunSource :
- Acta psychiatrica Scandinavica [ 1600-0447 ] ; 2014.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adult, Affective Disorders, Psychotic (drug therapy), Aged, Anti-Anxiety Agents (therapeutic use), Antidepressive Agents (therapeutic use), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (therapeutic use), Bipolar Disorder (drug therapy), Case-Control Studies, Clozapine (therapeutic use), Cohort Studies, Female, France, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Psychotic Disorders (drug therapy), Schizophrenia (drug therapy).
- MESH :
- chemical , therapeutic use : Anti-Anxiety Agents, Antidepressive Agents, Antiparkinson Agents, Antipsychotic Agents, Clozapine.
- geographic : France.
- drug therapy : Affective Disorders, Psychotic, Bipolar Disorder, Parkinson Disease, Psychotic Disorders, Schizophrenia.
- Adult, Aged, Case-Control Studies, Cohort Studies, Female, Humans, Male, Middle Aged.
Abstract
To explore the pattern of clozapine use in persons with severe mental illness and in persons with Parkinson's disease and the characteristics associated with early discontinuation in naturalistic conditions.
DOI: 10.1111/acps.12344
PubMed: 25302631
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25302631Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.</title><author><name sortKey="Verdoux, H" sort="Verdoux, H" uniqKey="Verdoux H" first="H" last="Verdoux">H. Verdoux</name><affiliation wicri:level="3"><nlm:affiliation>University of Bordeaux, U657, Bordeaux, France; INSERM, U657, Bordeaux, France; Centre Hospitalier Charles Perrens, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Bordeaux, U657, Bordeaux, France; INSERM, U657, Bordeaux, France; Centre Hospitalier Charles Perrens, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Pambrun, E" sort="Pambrun, E" uniqKey="Pambrun E" first="E" last="Pambrun">E. Pambrun</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25302631</idno><idno type="pmid">25302631</idno><idno type="doi">10.1111/acps.12344</idno><idno type="wicri:Area/PubMed/Corpus">000451</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000451</idno><idno type="wicri:Area/PubMed/Curation">000442</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000442</idno><idno type="wicri:Area/PubMed/Checkpoint">000442</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000442</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.</title><author><name sortKey="Verdoux, H" sort="Verdoux, H" uniqKey="Verdoux H" first="H" last="Verdoux">H. Verdoux</name><affiliation wicri:level="3"><nlm:affiliation>University of Bordeaux, U657, Bordeaux, France; INSERM, U657, Bordeaux, France; Centre Hospitalier Charles Perrens, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Bordeaux, U657, Bordeaux, France; INSERM, U657, Bordeaux, France; Centre Hospitalier Charles Perrens, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Pambrun, E" sort="Pambrun, E" uniqKey="Pambrun E" first="E" last="Pambrun">E. Pambrun</name></author></analytic><series><title level="j">Acta psychiatrica Scandinavica</title><idno type="eISSN">1600-0447</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Affective Disorders, Psychotic (drug therapy)</term><term>Aged</term><term>Anti-Anxiety Agents (therapeutic use)</term><term>Antidepressive Agents (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Bipolar Disorder (drug therapy)</term><term>Case-Control Studies</term><term>Clozapine (therapeutic use)</term><term>Cohort Studies</term><term>Female</term><term>France</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Psychotic Disorders (drug therapy)</term><term>Schizophrenia (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term><term>Antidepressive Agents</term><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Affective Disorders, Psychotic</term><term>Bipolar Disorder</term><term>Parkinson Disease</term><term>Psychotic Disorders</term><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Case-Control Studies</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To explore the pattern of clozapine use in persons with severe mental illness and in persons with Parkinson's disease and the characteristics associated with early discontinuation in naturalistic conditions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25302631</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>14</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.</ArticleTitle><Pagination><MedlinePgn>487-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12344</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the pattern of clozapine use in persons with severe mental illness and in persons with Parkinson's disease and the characteristics associated with early discontinuation in naturalistic conditions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A historical fixed cohort study of persons newly treated with clozapine was performed on a representative community-based sample of persons affiliated to the French health insurance system (n = 611,393). Treatment for Parkinson's disease was used as a proxy for this condition and lack of such treatment as a proxy for severe mental illness (SMI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalences of antipsychotic and clozapine use were 4.4% and <0.1% respectively. Of the 237 persons with a new outpatient prescription of clozapine, 25% were prescribed an antiparkinsonian treatment. In persons with SMI, the median duration of the index episode of clozapine treatment was 4.9 months (Interquartile range 1.0-20.5). Longer duration was independently associated with coprescription of anxiolytics or antidepressant. Few new additions of antipsychotics were observed during the clozapine episode.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Efforts have to be made to optimize clozapine treatment in real-world conditions. Considering the high frequency of persons with Parkinson's disease among clozapine users, further studies have to be performed in this population.</AbstractText><CopyrightInformation>© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verdoux</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Bordeaux, U657, Bordeaux, France; INSERM, U657, Bordeaux, France; Centre Hospitalier Charles Perrens, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pambrun</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clozapine</Keyword><Keyword MajorTopicYN="N">health insurance database</Keyword><Keyword MajorTopicYN="N">treatment duration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25302631</ArticleId><ArticleId IdType="doi">10.1111/acps.12344</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><noCountry><name sortKey="Pambrun, E" sort="Pambrun, E" uniqKey="Pambrun E" first="E" last="Pambrun">E. Pambrun</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Verdoux, H" sort="Verdoux, H" uniqKey="Verdoux H" first="H" last="Verdoux">H. Verdoux</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000567 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000567 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25302631
|texte= Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25302631" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |